Efavirenz decreases exposure to hormonal contraceptive implant
1 December 2014. Related: Conference reports, Antiretrovirals, Side effects.
Side effects
Increased risk of ART-related hepatotoxicity in HIV positive pregnant women
1 December 2014. Related: Conference reports, Antiretrovirals, Pregnancy, Side effects.
Efavirenz-associated gynaecomastia reported to the national HIV and TB healthcare workers hotline in South Africa
1 December 2014. Related: Conference reports, Antiretrovirals, Side effects.
Poppers-related maculopathy linked to permanent and serious vision loss
1 December 2014. Related: Side effects.
Risk of CVD or type-2 diabetes according to change in BMI after starting ART
1 October 2014. Related: Conference reports, Antiretrovirals, Side effects.
Rosuvastatin may be partially effective in moderating residual immune activation on ART
1 October 2014. Related: Conference reports, Side effects.
Kidney signal trouble worsens over 5 years in Japanese on tenofovir
1 October 2014. Related: Side effects, Coinfections and complications.
Bone mineral density linked to inflammatory markers in HIV positive people who are ART naïve
1 August 2014. Related: Side effects.
No increase death rate in HIV positive people with renal dysfunction receiving tenofovir in Zambia
27 May 2014. Related: Side effects.
Abacavir link to cardiovascular events in high-risk patients maintained in D:A:D study
24 March 2014. Related: Conference reports, Side effects.
Two percent rate of efavirenz discontinuation in an ART programme in Malawi
1 February 2014. Related: Conference reports, Antiretrovirals, Pregnancy, Side effects.
Efavirenz is associated with higher suicide risk in meta-analysis of four ACTG studies
1 December 2013. Related: Side effects.
Longitudinal changes in weight, lean body mass and bone mineral density in first-line combinations: ACTG 5205 substudy
1 October 2013. Related: Side effects.
ARVs and bone health: the role of NRTIs in second-line therapy
25 July 2013. Related: Conference reports, Side effects.
Ending global use of d4T: UNITAID to tip market to safer alternatives
25 July 2013. Related: Treatment access, Side effects.
Osteonecrosis in HIV positive patients is associated with increased levels of CRP and D-dimer
29 May 2013. Related: Side effects.
No impact of ART on progression or regression of anal squamous intraepithelial lesions
29 May 2013. Related: Side effects.
Incidence of cancers in Australian observational cohort
29 May 2013. Related: Side effects.
Statin use in HIV positive people
1 April 2013. Related: Conference reports, Side effects.
No impact of ART on progression or regression of anal squamous intraepithelial lesions
1 April 2013. Related: Side effects.
Osteonecrosis in HIV positive patients is associated with increased levels of CRP and D-dimer
1 April 2013. Related: Side effects.
Cognitive disorders are common in French cohort but are not HIV-related
1 April 2013. Related: Side effects.
Smoking is largest contributor to reduced life expectancy in Danish HIV cohort
1 February 2013. Related: Side effects.
Low bone mineral density in MSM irrespective of HIV status
1 February 2013. Related: Side effects.
Low incidence of liver-related deaths in HIV positive people without HBV and/or HCV co-infection
1 December 2012. Related: Side effects.
Rapid drop in mitochondria in fat biopsies within four weeks of d4T use
1 December 2012. Related: Side effects.
High dose multivitamin use in advanced HIV has no benefit to CD4 and viral load and may cause liver toxicity
1 December 2012. Related: Side effects.
Increased incidence of ischemic stroke amongst HIV positive cohort
1 October 2012. Related: Side effects.
First report: atazanavir-related gallstones (cholelithiasis)
1 August 2012. Related: Conference reports, Antiretrovirals, Side effects.
High prevalence of peripheral neuropathy in children taking d4T in rural South Africa
1 August 2012. Related: Conference reports, Paediatric care, Side effects.
Skeletal muscle toxicity and raltegravir
1 August 2012. Related: Conference reports, Antiretrovirals, Side effects.
Proteinuria as a potential early marker of tenofovir-related renal toxicity
1 August 2012. Related: Conference reports, Side effects.
Earlier and greater comorbidities reported in HIV positive cohort
1 August 2012. Related: Conference reports, Side effects.
Theratechnologies withdraw EU application for tesamorelin (Egrifta)
1 August 2012. Related: Side effects.
Recent studies on HIV, ART and osteoporotic fracture risk
1 August 2012. Related: Side effects.
One third of HIV positive people at five UK clinics have symptomatic depression: link to adherence and viral suppression – 40% cases are untreated
1 June 2012. Related: Conference reports, Side effects, Coinfections and complications.
Intranasal and topical corticosteroids and risk of Cushing’s symptoms in HIV patients on ritonavir-based combinations
1 June 2012. Related: Conference reports, PK and drug interactions, Side effects.
Outcomes from switches to atazanavir/r in London
1 June 2012. Related: Conference reports, Antiretrovirals, Side effects.
20% people switch Atripla due to efavirenz side effects: late switches are common
1 June 2012. Related: Side effects.
Risk factors associated with End Stage Renal Disease (ESRD) in HIV positive patients in the US Veterans Association (VA) cohort
1 June 2012. Related: Side effects.
Associations between tenofovir use and renal complications in VA cohort
1 June 2012. Related: Side effects.
No association between atazanavir and MI or stroke in D:A:D study
1 April 2012. Related: Conference reports, Side effects, Coinfections and complications.
FDA reject capsaicin patch for HIV-related neuropathy
1 April 2012. Related: Side effects.
Hearing loss not associated with HIV in MACS and WIHS cohorts
1 August 2011. Related: Conference reports, Side effects, Coinfections and complications.
More metabolic abnormalities in children receiving a PI compared to NNRTI in NEVEREST study
1 August 2011. Related: Conference reports, Paediatric care, Side effects.
Lopinavir/ritonavir oral solution toxicity in neonates
1 August 2011. Related: Conference reports, Paediatric care, Side effects.
Tenofovir associated with fewer side-effect related switches compared to AZT or d4T in first-line treatment
1 May 2011. Related: Side effects.
Meta-analysis of RCTs support use of smoked cannabis to treat HIV-related peripheral neuropathy
1 February 2011. Related: Side effects.
Nevirapine exposure was not associated with hypersensitivity in patients from Malawi
1 December 2010. Related: Conference reports, Antiretrovirals, Side effects.
UK studies on bone health: increasedfracture rates reported in HIV-positive people
1 December 2010. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Muscle weakness or pain analysed as possible raltegravir side effect
1 December 2010. Related: Conference reports, Antiretrovirals, Side effects.
Bio-Alcamid associated with unacceptable risk of complications: no longer recommended as a treatment for facial lipoatrophy
1 December 2010. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
FDA safety updates to antiretroviral labels
1 December 2010. Related: Antiretrovirals, Side effects.
Update to US saquinavir label
1 December 2010. Related: Antiretrovirals, Side effects.
FDA approves tesamorelin for reduction of central fat accumulation
1 December 2010. Related: Side effects, Lipodystrophy and metabolic complications.
High rates of bone loss and progression with HIV in longitudinal study
1 October 2010. Related: Conference reports, Antiretrovirals, Side effects.
Development of chronic kidney disease and antiretroviral use in EuroSIDA cohortsince 2004
1 October 2010. Related: Antiretrovirals, Side effects.
Tesamorelin for reduction of central fat accumulation: regulatory decision delayed in the US
1 October 2010. Related: Side effects, Lipodystrophy and metabolic complications.
75% HIV-positive children have insufficient levels of Vitamin D
1 June 2010. Related: Conference reports, Paediatric care, Side effects, Lipodystrophy and metabolic complications.
High rates of osteopenia and osteoporosis: importance of DEXA monitoring
1 June 2010. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
ACTG 5205: atazanavir/ritonavir vs efavirenz in treatment naive patients
2 April 2010. Related: Conference reports, Antiretrovirals, Side effects, Lipodystrophy and metabolic complications.
HIV positive people in the HOPS cohort have 4-fold risk of fracture compared to general population in the US
2 April 2010. Related: Conference reports, Side effects.
Vitamin D deficiencies in HIV management
2 April 2010. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Central fat accumulation remains a significant problem in patients starting HAART after 2005 with higher incidence in women compared to men
21 February 2010. Related: Conference reports, Women's health, Side effects, Lipodystrophy and metabolic complications.
Alendronate improves bone mineral density in HIV positive people with osteoporosis at 96 weeks
21 February 2010. Related: Conference reports, Side effects.